ARI 1: beta-lactamase-mediated imipenem resistance in Acinetobacter baumannii
1Department of Medical Microbiology, University of Edinburgh Medical School, Edinburgh, UK.
Abstract:
A strain of Acinetobacter baumannii 6B92 isolated from the blood culture of a patient at the Edinburgh Royal Infirmary i 1985 was found to be resistant to imipenem, all classes of cephalosporins and penicillins. Extraction of the soluble proteins of the cell and isoelectric focusing revealed the presence of two beta-lactamases: a chromosomal cephalosporinase of high pI (> pI 9.0) and a novel beta-lactomase of pI 6.65 named ARI 1 (Acinetobacter resistant to imipenem). Despite the fact that original clinical isolate could be 'cured' of its resistance to imipenem and penicillins by growing in the presence of ethidium bromide with the concurrent loss of the ARI 1 enzymes, no resistance plasmid was visualised or transferred. The ARI 1 beta-lactamase hydrolysed penicillin, ampicillin and cephaloridine slowly during enzyme assay but inactivation of imipenem could only be demonstrated by microbiological means. The molecular size of the ARI 1 enzyme was 23 kDa and it was not inhibited by EDTA, p-CMB, or clavulanate.
Insights
Acinetobacter baumannii strain 6B92 exhibited resistance to multiple antibiotics, including imipenem. Researchers identified a novel beta-lactamase, ARI 1, responsible for this resistance, which was lost when the bacteria were treated with ethidium bromide.
Area of Science:
- Microbiology
- Biochemistry
- Molecular Biology
Background:
- Acinetobacter baumannii is an opportunistic pathogen frequently associated with hospital-acquired infections.
- Antibiotic resistance in A. baumannii, particularly to carbapenems like imipenem, poses a significant clinical challenge.
- Beta-lactamases are enzymes that confer resistance to beta-lactam antibiotics by hydrolyzing their core structure.
Purpose of the Study:
- To characterize the beta-lactamase enzymes responsible for imipenem and broad-spectrum cephalosporin resistance in a clinical isolate of Acinetobacter baumannii.
- To investigate the genetic basis of this antibiotic resistance, including the potential role of plasmids.
Main Methods:
- Isolation and characterization of a resistant Acinetobacter baumannii strain (6B92).
- Protein extraction, isoelectric focusing, and enzyme assays to identify and characterize beta-lactamases.
- Treatment with ethidium bromide to assess the stability of resistance and the role of plasmids.
- Determination of enzyme molecular size and inhibition profiles.
Main Results:
- The resistant strain possessed two beta-lactamases: a high pI chromosomal cephalosporinase and a novel beta-lactamase, ARI 1 (pI 6.65).
- Treatment with ethidium bromide cured the imipenem and penicillin resistance, coinciding with the loss of ARI 1, but no resistance plasmid was detected.
- ARI 1 slowly hydrolyzed penicillin, ampicillin, and cephaloridine, and inactivated imipenem via a mechanism demonstrable only microbiologically.
- ARI 1 has a molecular size of 23 kDa and is not inhibited by common inhibitors like EDTA, p-CMB, or clavulanate.
Conclusions:
- A novel beta-lactamase, ARI 1, contributes significantly to imipenem resistance in Acinetobacter baumannii.
- The resistance mechanism associated with ARI 1 may be chromosomally encoded or involve a non-visualized/non-transferable plasmid.
- Further investigation is needed to elucidate the precise genetic basis and mechanism of imipenem inactivation by ARI 1.
Related Concept Videos
Mechanism of Antibiotic Resistance in MRSA
Development of Antibiotic Resistance
Clinical Significance of Antibiotic Resistance
Inhibitors of Gram-positive Cell Wall Synthesis
Atypical Pneumonia
Production of Antibiotics
